During the recent session, Gossamer Bio Inc (NASDAQ:GOSS)’s traded shares were 0.42 million, with the beta value of the company hitting 1.89. At the last check today, the stock’s price was $1.21, reflecting an intraday gain of 2.12% or $0.03. The 52-week high for the GOSS share is $1.60, that puts it down -32.23 from that peak though still a striking 58.68% gain since the share price plummeted to a 52-week low of $0.50. The company’s market capitalization is $273.06M, and the average trade volume was 1.59 million shares over the past three months.
Gossamer Bio Inc (GOSS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. GOSS has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.17.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Gossamer Bio Inc (GOSS) registered a 2.12% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.12% in intraday trading to $1.21, hitting a weekly high. The stock’s 5-day price performance is 1.26%, and it has moved by 18.14% in 30 days. Based on these gigs, the overall price performance for the year is -16.90%.
The consensus price target of analysts on Wall Street is $4, which implies an increase of 69.75% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $5 respectively. As a result, GOSS is trading at a discount of -313.22% off the target high and -65.29% off the low.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 7.02M as predicted by 9 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 3.48M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.99%. While earnings are projected to return 76.06% in 2025, the next five years will return 26.42% per annum.
GOSS Dividends
Gossamer Bio Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
The next largest institutional holding, with 13.31 million shares, is of ARTAL GROUP S.A.’s that is approximately 5.8832% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $11.99 million.
Also, the Mutual Funds coming in first place with the largest holdings of Gossamer Bio Inc (GOSS) shares are Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. Data provided on Dec 31, 2024 indicates that Fidelity Select Portfolios – Biotechnology owns about 7.91 shares. This amounts to just over 3.49 percent of the company’s overall shares, with a $9.58 million market value. The same data shows that the other fund manager holds slightly less at 7.84, or about 3.46% of the stock, which is worth about $9.49 million.
